Cargando…
Dry eye syndrome: developments and lifitegrast in perspective
Dry eye (DE) is a chronic ocular condition with high prevalence and morbidity. It has a complex pathophysiology and is multifactorial in nature. Chronic ocular surface inflammation has emerged as a key component of DE that is capable of perpetuating ocular surface damage and leading to symptoms of o...
Autores principales: | Lollett, Ivonne V, Galor, Anat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774475/ https://www.ncbi.nlm.nih.gov/pubmed/29391773 http://dx.doi.org/10.2147/OPTH.S126668 |
Ejemplares similares
-
Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019) -
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba, Charles P, et al.
Publicado: (2016) -
Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016) -
Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017) -
Parallel ocular and serologic course in a patient with early Sjogren's syndrome markers
por: Phung, Lam, et al.
Publicado: (2017)